COMMUNIQUÉS West-GlobeNewswire

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
17/08/2026
— First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO ® as the backbone therapy across EGFRm lung cancer — HONG [...]
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
17/08/2026
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in [...]
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
14/08/2026
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion [...]
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
14/08/2026
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported [...]
Precipio Announces Q2-2026 Financial Results
14/08/2026
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, Conn., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( [...]
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
14/08/2026
Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with [...]
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, [...]
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
14/08/2026
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, [...]
BioStem Technologies to Present at the Sidoti MicroCap Conference
14/08/2026
POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/08/2026
CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
4DMT Announces New Employment Inducement Grants
14/08/2026
EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
14/08/2026
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' [...]
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
14/08/2026
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics [...]
Solana Company Reports Second Quarter 2026 Financial Results
14/08/2026
PHILADELPHIA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
14/08/2026
Quarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE [...]
Profound Medical Announces Management Change
14/08/2026
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI ( [...]
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
14/08/2026
Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study Completed the April 2026 private placement and [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
14/08/2026
WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027
14/08/2026
MINNEAPOLIS, MN, US, Aug. 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading [...]

Pages